266 related articles for article (PubMed ID: 11987436)
1. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
Kobelt G; Jönsson L; Miltenburger C; Jönsson B
Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Henriksson F; Fredrikson S; Jönsson B
Int J Technol Assess Health Care; 2000; 16(3):768-80. PubMed ID: 11028132
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Fredrikson S
Eur J Health Econ; 2003; 4(1):50-9. PubMed ID: 15609169
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
[TBL] [Abstract][Full Text] [Related]
5. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
6. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
Touchette DR; Durgin TL; Wanke LA; Goodkin DE
Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[TBL] [Abstract][Full Text] [Related]
8. [The efficiency and cost-utility ratio of interferon beta in the treatment of multiple sclerosis in Andalusia].
Medina-Redondo F; Herrera-Carranza J; Sanabria C; Navarro G; García-Moreno JM; Gamero-García MA; Páramo MD; Ruiz-Peña JL; Izquierdo G
Rev Neurol; 2004 Jul 1-15; 39(1):1-6. PubMed ID: 15257519
[TBL] [Abstract][Full Text] [Related]
9. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
10. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
Nuijten M; Mittendorf T
Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
[TBL] [Abstract][Full Text] [Related]
11. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
12. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
13. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.
Tappenden P; Saccardi R; Confavreux C; Sharrack B; Muraro PA; Mancardi GL; Kozak T; Farge-Bancel D; Madan J; Rafia R; Akehurst R; Snowden J
Bone Marrow Transplant; 2010 Jun; 45(6):1014-21. PubMed ID: 19855441
[TBL] [Abstract][Full Text] [Related]
14. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
Kobelt G; Texier-Richard B; Lindgren P
Mult Scler; 2009 Jun; 15(6):741-51. PubMed ID: 19383645
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
[TBL] [Abstract][Full Text] [Related]
16. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP
Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392
[TBL] [Abstract][Full Text] [Related]
18. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.
Nuijten MJ; Hutton J
Value Health; 2002; 5(1):44-54. PubMed ID: 11873383
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
